rs387906236
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000038.6(APC):c.4612_4613del(p.Glu1538IlefsTer5) variant causes a frameshift change. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.0 ( 0 hom., cov: 32)
Failed GnomAD Quality Control
Consequence
APC
NM_000038.6 frameshift
NM_000038.6 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 4.26
Genes affected
APC (HGNC:583): (APC regulator of WNT signaling pathway) This gene encodes a tumor suppressor protein that acts as an antagonist of the Wnt signaling pathway. It is also involved in other processes including cell migration and adhesion, transcriptional activation, and apoptosis. Defects in this gene cause familial adenomatous polyposis (FAP), an autosomal dominant pre-malignant disease that usually progresses to malignancy. Mutations in the APC gene have been found to occur in most colorectal cancers, where disease-associated mutations tend to be clustered in a small region designated the mutation cluster region (MCR) and result in a truncated protein product. [provided by RefSeq, Jun 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. There are 31 pathogenic variants in the truncated region.
PP5
Variant 5-112840204-CAG-C is Pathogenic according to our data. Variant chr5-112840204-CAG-C is described in ClinVar as [Pathogenic]. Clinvar id is 823.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr5-112840204-CAG-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
APC | NM_000038.6 | c.4612_4613del | p.Glu1538IlefsTer5 | frameshift_variant | 16/16 | ENST00000257430.9 | NP_000029.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
APC | ENST00000257430.9 | c.4612_4613del | p.Glu1538IlefsTer5 | frameshift_variant | 16/16 | 5 | NM_000038.6 | ENSP00000257430 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00 AC: 0AN: 152074Hom.: 0 Cov.: 32 FAILED QC
GnomAD3 genomes
AF:
AC:
0
AN:
152074
Hom.:
Cov.:
32
FAILED QC
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome Data not reliable, filtered out with message: AC0;AS_VQSR AF: 0.00 AC: 0AN: 152074Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74274
GnomAD4 genome
Data not reliable, filtered out with message: AC0;AS_VQSR
AF:
AC:
0
AN:
152074
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74274
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Familial adenomatous polyposis 1 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 13, 2023 | This sequence change creates a premature translational stop signal (p.Glu1538Ilefs*5) in the APC gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 1306 amino acid(s) of the APC protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with familial adenomatous polyposis (PMID: 8162051, 8594558, 20223039, 20513532, 20685668, 21643010, 21779980, 22987206). ClinVar contains an entry for this variant (Variation ID: 823). This variant is expected to disrupt the EB1 and HDLG binding sites, which mediate interactions with the cytoskeleton (PMID: 15311282, 17293347). While functional studies have not been performed to directly test the effect on APC protein function, this suggests that disruption of the C-terminal portion of the protein is functionally important. A different truncation (p.Tyr2645Lysfs*14) that lies downstream of this variant has been determined to be pathogenic (PMID: 9824584, 1316610, 27081525, 8381579, 22135120, Invitae). This suggests that deletion of this region of the APC protein is causative of disease. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Nov 28, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | May 11, 2023 | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Jul 20, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Jul 05, 2023 | - - |
Familial multiple polyposis syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jul 28, 2020 | The p.Glu1538IlefsX5 variant in APC has been previously reported in at least 6 individuals with APC-associated polyposis conditions: 3 with familial adenomatous polyposis (FAP), 3 individuals with Gardner syndrome, and 4 individuals with suspected FAP (Gayther 1994 PMID: 8162051, Armstrong 1997 PMID: 9375853, Friedl 2005 PMID: 20223039, Jang 2010 PMID: 20513532, Lagarde 2010 PMID: 20685668, Jarry 2011 PMID: 21779980, Rohlin 2011 PMID: 21643010, Schwarzová 2013 PMID: 22987206). This variant was also reported by other clinical laboratories in ClinVar (Variation ID: 823) and was absent from large population studies. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 1538 and leads to a premature termination codon 5 amino acids downstream. This termination codon occurs within the last exon and is, therefore, likely to escape nonsense mediated decay (NMD) and result in a truncated protein that is missing ~46% of the coding region, with 1302 amino acids removed. Truncating variants in the last exon of APC, including multiple variants downstream of this variant, have been reported in individuals with FAP. Furthermore, this truncation is predicted to remove the EB1 and APC-basic domains of the APC protein, and in vitro studies have shown that these domains are important regions for APC-mediated microtubule stability and F-actin interactions (Moseley 2007 PMID 17293347, Wen 2004 PMID 15311282). In summary, this variant meets criteria to be classified as pathogenic for APC-associated polyposis conditions, including autosomal dominant FAP and Gardner syndrome. ACMG/AMP Criteria applied: PVS1, PM2, PS4_Strong. - |
Gastric cancer;C0346629:Colorectal cancer;C1851124:Desmoid disease, hereditary;C2239176:Hepatocellular carcinoma;C2713442:Familial adenomatous polyposis 1;C4749917:Gastric adenocarcinoma and proximal polyposis of the stomach Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago | Mar 30, 2021 | APC NM_000038.5 exon 15 p.Glu1538Ilefsx5 (c.4612_4613del): This variant has been reported in the literature in at least 8 individuals with Familial Adenomatous Polyposis (FAP) (Gayther 1994 PMID:8162051, Friedl 2005 PMID:20223039, Jang 2010 PMID:20513532, Lagarde 2010 PMID:20685668, Jarry 2011 PMID:21779980, Rohlin 2011 PMID:21643010, Schwarzova 2013 PMID:22987206). This variant is not present in large control databases. This variant is present in ClinVar (Variation ID:823). Evolutionary conservation and computational predictive tools for this variant are limited or unavailable. This variant is a deletion of two nucleotides and creates a premature stop codon 5 amino acids downstream from this location which results in an absent or abnormal protein. Loss of function variants are a known mechanism of disease for this gene (Zhang 2017 PMID:28423402). Of note, this variant occurs within the last exon of this gene; due to its position, it is possible that this protein may escape nonsense mediated decay. However this variant is predicted to affect approximately 45% of the protein and other variants downstream have been reported as Pathogenic. Furthermore, evidence in the literature suggests that variants cluster in this region (Gayther 1994 PMID:8162051). In summary, this variant is classified as pathogenic based on the data above. - |
Gardner syndrome Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 1997 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 28, 2015 | The c.4612_4613delGA pathogenic mutation, located in coding exon 15 of the APC gene, results from a deletion of two nucleotides between nucleotide positions 4612 and 4613, causing a translational frameshift with a predicted alternate stop codon. This mutation has been detected in multiple individuals with clinical diagnoses of AFAP or FAP (Friedl W, et al. Hered Cancer Clin Pract 2005;3(3):95-114, Vandrovcová J, et a. Hum. Mutat. 2004;23(4):397, Jang YH, et al. Cancer Genet. Cytogenet. 2010;200(1):34-9, Gayther SA, et al. Hum. Mol. Genet. 1994;3(1):53-6, Armstrong JG, et al. Hum. Mutat. 1997;10(5):376-80). In addition to the clinical data presented in the literature, since frameshifts are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at